DK2386557T3 - Hidtil ukendte substituerede imidazoquinoliner - Google Patents

Hidtil ukendte substituerede imidazoquinoliner Download PDF

Info

Publication number
DK2386557T3
DK2386557T3 DK11175040.2T DK11175040T DK2386557T3 DK 2386557 T3 DK2386557 T3 DK 2386557T3 DK 11175040 T DK11175040 T DK 11175040T DK 2386557 T3 DK2386557 T3 DK 2386557T3
Authority
DK
Denmark
Prior art keywords
alkyl
aryl
compound
butyl
formula
Prior art date
Application number
DK11175040.2T
Other languages
English (en)
Inventor
Volker Gekeler
Thomas Maier
Astrid Zimmermann
Hans-Peter Hofmann
Sanjeev A Kulkarni
Anil P Jagtap
Ganesh S Chaure
Original Assignee
Biontech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Ag filed Critical Biontech Ag
Application granted granted Critical
Publication of DK2386557T3 publication Critical patent/DK2386557T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (12)

1. Forbindelse med formel I:
(i) hvori Ri er udvalgt fra gruppen bestående af: - H, al kyl, alkynyl, aryl, alkoxy, heterocyclyl og heteroaryl, hvor alkyl, alkynyl, aryl, alkoxy, heterocyclyl eller heteroaryl kan være usub-stitueret eller substitueret med en eller flere substituenter udvalgt fra gruppen bestående af: -H, -OH, halogen, -CO-N(R4)2, -N(R4)2, -CO-Ci-io-alkyl, -CO-O-Ci-10-alkyl, -N3, aryl og heterocyclyl, hvor hvert R4 uafhængigt er udvalgt fra gruppen bestående af: -H, -C1-10 alkyl, -C1-10 alkyl-aryl eller aryl; A er Ci-C6-alkyl; B er -N(R2)(R3); R2 erH R3 er udvalgt fra gruppen bestående af: aryl, heteroaryl, cycloalkyl og heterocyclyl, hvor aryl, heteroaryl, cycloalkyl eller heterocyclyl kan være usubstitueret eller substitueret med en eller flere substituenter udvalgt fra gruppen bestående af: -H, alkyl, alkenyl, alkoxy, halogen, -OH, -N3, trifluormethyl, -alkyl-aryl, -O-alkyl-aryl, -CO-aryl, aryl, heterocyclyl, heteroaryl, -CO-heteroaryl, -CO-O-alkyl, -CO-N-alkyl, -CO-N-aryl, eller farmaceutisk acceptable solvater, salte, N-oxider eller stereoisomerer deraf eller kombinationer deraf.
2. Forbindelse med formel I ifølge krav 1, hvor R3 er heterocyclyl, som kan være usubstitueret eller substitueret med en eller flere substituenter udvalgt fra gruppen bestående af: -H, alkyl, alkenyl, alkoxy, halogen, -OH, -N3, trifluormethyl, -alkyl-aryl, -O-alkyl-aryl, -CO-aryl, aryl, heterocyclyl, heteroaryl, -CO-heteroaryl, -CO-O-alkyl, -CO-N-alkyl, -CO- N-aryl, fortrinsvis udvalgt fra gruppen bestående af: -H, alkyl, alkenyl, halogen og -OH.
3. Forbindelse med formel I ifølge et hvilket som helst af kravene 1-2, hvor R3 er udvalgt fra gruppen bestående af: dioxo-tetrahydrothiophenyl, piperidinyl, tetrahydrofuranyl, pyrididin, tetrahydropyranyl og azabicyclooctanyl, hvoraf hver eventuelt kan være substitueret med en eller flere grupper, udvalgt fra gruppen omfattende halogen, hydroxyl, aryl, alkyl, alkoxy, trifluormethyl eller kombinationer deraf.
4. Forbindelse med formel I ifølge et hvilket som helst af kravene 1-3, hvor R-i er alkyl, fortrinsvis ethyl.
5. Forbindelse ifølge krav 1, som er: 2-ethyl-1-[4-(tetrahydro-2H-pyran-4-ylamino)butyl]-1 H-imidazo[4,5-c]quinolin-4-amin, 1 -[4-(1 -azabicyclo[2.2.2]oct-3-ylamino)butyl]-2-ethyl-1 H-imidazo[4,5-c]quinolin-4-amin eller 1 -{4-[(1,1 -dioxido-3,4-dihydro-2H-thiochromen-4-yl)amino]butyl}-2-ethyl-1 H-imidazo[4,5-c]quinolin-4-amin eller farmaceutisk acceptable solvater, salte, N-oxider eller stereoisomerer deraf eller kombinationer deraf.
6. Forbindelse ifølge et hvilket som helst af kravene 1 til 5 til anvendelse som et medikament.
7. Farmaceutisk sammensætning omfattende en terapeutisk virksom mængde af en forbindelse med formel I ifølge et hvilket som helst af kravene 1 til 5 i kombination med en farmaceutisk acceptabel bærer.
8. Farmaceutisk sammensætning ifølge krav 7 omfattende en mængde af forbindelsen med formel I, eller farmaceutisk acceptable solvater, salte, N-oxider eller stereoisomerer deraf eller kombinationer deraf, der er tilstrækkelig til at tilføre en dosis på 100 ng/kg til 50 mg/kg, fortrinsvis 10 pg/kg til 5 mg/kg af forbindelsen til individet.
9. Anvendelse af en forbindelse ifølge et hvilket som helst af kravene 1 til 5 eller en farmaceutisk sammensætning ifølge krav 7 eller 8 til fremstilling af et medikament til behandling af en virussygdom eller neoplastisk sygdom.
10. Forbindelse ifølge et hvilket som helst af kravene 1 til 5 eller en farmaceutisk sammensætning ifølge krav 7 eller 8 til anvendelse ved behandling af en cancer udvalgt fra gruppen omfattende cancer i brystet, blæren, knogler, hjernen, det centrale og perifere nervesystem, colon, endokrine kirtler, spiserøret, endometrium, kimceller, hoved og hals, nyre, lever, lunge, larynx og hypopharynx, mesotheliom, sarkom, æggestok, pancreas, prostata, rektum, nyre, tyndtarmen, blødt væv, testikler, mave, hud, urinleder, vagina og vulva; nedarvede cancertyper, retinoblastom og Wilms tumor; leukæmi, lymfom, non-Hodgkins sygdom, kronisk og akut myeloid leukæmi, akut lymfoblastisk leukæmi, Hodgkins sygdom, myelomatose og T-celle-lymfom; myelodyspla-stisk syndrom, plasmacelleneoplasi, paraneoplastiske syndromer, cancere med ukendt primært sted og aids-relaterede maligniteter.
11. Forbindelse ifølge et hvilket som helst af kravene 1 til 5 eller en farmaceutisk sammensætning ifølge krav 9 eller 10 til anvendelse ved behandling af en medicinsk tilstand udvalgt fra gruppen omfattende kønsvorter; vorter; fodvorter; hepatitis B; hepatitis C; Herpes Simplex type I og type II; mol-luscum contagiosum; hiv; CMV; VZV; intraepiteliale neoplasier, herunder cervikal intraepitelial neoplasi, human papillomavirus (HPV) og associerede neoplasier; svampesygdomme, herunder candida, aspergillus og kryptokok-meningitis; neoplastiske sygdomme, herunder basalcellekarcinom, hårcelle-leukæmi, Kaposis sarkom, renalcellekarcinom, pladecellekarcinom, myeloid leukæmi, myelomatose, melanom, non-Hodgkins lymfom, kutant T-celle-lymfom og andre cancertyper; parasitsygdomme, herunder pneumocystis carinii, cryptosporidiose, histoplasmose, toksoplasmose, trypanosom infektion og leishmaniasis; bakterieinfektioner, herunder tuberkulose og myco-bacterium avium; eksem; eosinofili; essentiel trombocytæmi; spedalskhed; multipel sklerose; Ommens syndrom; diskoid lupus; Bowens sygdom; Bowe-noid papulosis; atopiske sygdomme, herunder atopisk dermatitis; astma; allergi; allergisk rhinitis; systemisk lupus erythematosus; tilbagevendende svampesygdomme, parodontitis og chlamydia; eller til anvendelse som en vaccine-adjuvans til cellemedieret immunitet; eller til anvendelse til forbedring eller stimulering af heling af sår, herunder kroniske sår.
12. Anvendelse af en forbindelse ifølge et hvilket som helst af kravene 1 til 5 i fremstillingen af et medikament.
DK11175040.2T 2008-03-24 2009-03-23 Hidtil ukendte substituerede imidazoquinoliner DK2386557T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN614MU2008 2008-03-24
EP09724784.5A EP2276486B1 (en) 2008-03-24 2009-03-23 Novel substituted imidazoquinolines

Publications (1)

Publication Number Publication Date
DK2386557T3 true DK2386557T3 (da) 2018-04-23

Family

ID=40718842

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09724784.5T DK2276486T3 (da) 2008-03-24 2009-03-23 Nye substituerede imidazo-quinoliner
DK11175040.2T DK2386557T3 (da) 2008-03-24 2009-03-23 Hidtil ukendte substituerede imidazoquinoliner

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK09724784.5T DK2276486T3 (da) 2008-03-24 2009-03-23 Nye substituerede imidazo-quinoliner

Country Status (25)

Country Link
US (3) US9073913B2 (da)
EP (2) EP2386557B1 (da)
JP (3) JP5670876B2 (da)
KR (1) KR101606219B1 (da)
CN (2) CN103396415B (da)
AU (2) AU2009228769C1 (da)
BR (1) BRPI0909317B1 (da)
CA (1) CA2719544C (da)
CY (1) CY1114648T1 (da)
DK (2) DK2276486T3 (da)
EA (2) EA023556B1 (da)
ES (2) ES2667054T3 (da)
HK (1) HK1152238A1 (da)
HR (1) HRP20131139T1 (da)
IL (1) IL208220A (da)
ME (1) ME02124B (da)
MX (2) MX2010010511A (da)
NZ (2) NZ599446A (da)
PL (1) PL2276486T3 (da)
PT (1) PT2276486E (da)
RS (1) RS53059B (da)
SG (1) SG189692A1 (da)
SI (1) SI2276486T1 (da)
UA (1) UA105764C2 (da)
WO (1) WO2009118296A2 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
CN103396415B (zh) * 2008-03-24 2016-08-10 4Sc股份有限公司 新的取代的咪唑并喹啉化合物
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
ES2644286T3 (es) 2009-10-22 2017-11-28 Gilead Sciences, Inc. Derivados de purina o deazapurina útiles para el tratamiento de (entre otros) infecciones víricas
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
BR112013022397A2 (pt) 2011-03-02 2017-09-26 Derek O’Hagan vacinas combinadas com doses menores de antígeno e/ou adjuvante
SI3892295T1 (sl) 2011-05-24 2023-09-29 BioNTech SE Individualizirana cepiva proti raku
IN2014CN02152A (da) 2011-09-01 2015-09-04 Novartis Ag
EP2822589A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of rabies virus immunogens
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
AU2013229432A1 (en) 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
RU2015106930A (ru) 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
KR20150065878A (ko) 2012-10-12 2015-06-15 글락소스미스클라인 바이오로지칼즈 에스.에이. 조합 백신에서 사용하기 위한 가교되지 않은 무세포 백일해 항원
WO2014082729A1 (en) 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
JP2016521282A (ja) 2013-05-10 2016-07-21 ノバルティス アーゲー インフルエンザワクチンにおけるナルコレプシーのリスクの回避
CA2922320C (en) 2013-08-28 2022-11-22 Pci Biotech As Enhanced photochemical internalisation using a tlr ligand
MX2016012538A (es) 2014-03-26 2016-12-14 Glaxosmithkline Biologicals Sa Antigenos estafilococicos mutantes.
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
CN104800843B (zh) * 2015-04-02 2017-07-04 中国农业科学院兰州兽医研究所 一种用于弓形虫感染预防的药剂及应用
JP2018521016A (ja) 2015-06-03 2018-08-02 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ ＩＬ−２３−ｐ１９ワクチン
WO2017005851A1 (en) 2015-07-07 2017-01-12 Affiris Ag Vaccines for the treatment and prevention of ige mediated diseases
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
EP3380126A4 (en) 2015-11-25 2019-07-24 LegoChem Biosciences, Inc. ANTIBODY-MEDICINAL CONJUGATES COMPRISING BRANCHED LINKS AND RELATED METHODS
MX2018007319A (es) * 2015-12-14 2018-09-06 Glaxosmithkline Biologicals Sa Imidazoquinolinas pegiladas como agonistas tlr7 y tlr8.
WO2019048036A1 (en) * 2017-09-06 2019-03-14 Biontech Ag SUBSTITUTED IMIDAZOQUINOLINES
HUE058995T2 (hu) 2017-09-06 2022-10-28 BioNTech SE Szubsztituált imidazokinolinok mint a TLR7 agonistái
EP3728255B1 (en) * 2017-12-20 2022-01-26 3M Innovative Properties Company Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
TW202012395A (zh) 2018-04-14 2020-04-01 德商４Ｓｃ製藥公司 用於治療癌症的包含組蛋白去乙醯酶（hdac）抑制劑和tlr7 激動劑和/或tlr8 激動劑的藥物組合產品
US10906923B1 (en) * 2019-02-07 2021-02-02 Canwell Biotech Limited Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof
CN113518775A (zh) * 2019-03-07 2021-10-19 生物技术公司 用于制备经取代的咪唑并喹啉的方法
BR112022008039A2 (pt) * 2019-10-29 2022-07-12 Prime Reach Trading Ltd Compostos de 4-amino-imidazoquinolina e usos relacionados
WO2022161420A1 (zh) * 2021-01-28 2022-08-04 上海翊石医药科技有限公司 一类芳杂环类化合物及其制备方法和用途
WO2023209441A1 (en) * 2022-04-29 2023-11-02 Legochem Biosciences, Inc. Imidazo[4,5-c]pyridine derivative compounds as tlr7/8 modulators
CN115181117B (zh) * 2022-08-08 2024-05-17 中国医学科学院医学生物学研究所 一种s构型手性分子化合物及其制备方法和作为疫苗佐剂的应用
CN116731015A (zh) * 2023-05-18 2023-09-12 深圳威科森生物医药科技有限公司 咪唑并喹啉化合物及其制备方法、应用和组合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015582A1 (en) * 1991-03-01 1992-09-17 Minnesota Mining And Manufacturing Company 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES
JP4101302B2 (ja) * 1997-01-09 2008-06-18 テルモ株式会社 新規アミド誘導体および合成中間体
JPH11222432A (ja) * 1998-02-03 1999-08-17 Terumo Corp インターフェロンを誘起するアミド誘導体を含有する外用剤
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6376669B1 (en) * 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
EP1455700A4 (en) * 2001-11-16 2007-02-14 3M Innovative Properties Co METHODS AND COMPOSITIONS RELATED TO MRI COMPOUNDS AND TO TOLL-TYPE RECEPTOR (TLR) PATHWAYS
NZ532769A (en) * 2001-11-29 2005-12-23 3M Innovative Properties Co Pharmaceutical formulations comprising an immune response modifier
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
WO2004071459A2 (en) * 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
JP2006519020A (ja) * 2003-02-27 2006-08-24 スリーエム イノベイティブ プロパティズ カンパニー Ｔｌｒ介在生物活性の選択的調節
KR20050107497A (ko) * 2003-03-07 2005-11-11 쓰리엠 이노베이티브 프로퍼티즈 컴파니 1-아미노 1ｈ-이미다조퀴놀린
US20040191833A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
MY157827A (en) * 2003-06-27 2016-07-29 3M Innovative Properties Co Sulfonamide substituted imidazoquinolines
JP4913593B2 (ja) * 2003-08-14 2012-04-11 スリーエム イノベイティブ プロパティズ カンパニー 脂質修飾された免疫応答調整剤
CN1906192A (zh) * 2003-11-14 2007-01-31 3M创新有限公司 羟胺取代的咪唑环化合物
EP1685129A4 (en) * 2003-11-14 2008-10-22 3M Innovative Properties Co OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
CA2547085A1 (en) 2003-11-25 2005-06-09 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US20070166384A1 (en) * 2004-04-09 2007-07-19 Zarraga Isidro Angelo E Methods , composition and preparations for delivery of immune response modifiers
CA2564855A1 (en) * 2004-04-28 2005-10-28 3M Innovative Properties Company Compositions and methods for mucosal vaccination
US20080015184A1 (en) 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
US20070259881A1 (en) 2004-06-18 2007-11-08 Dellaria Joseph F Jr Substituted Imidazo Ring Systems and Methods
WO2006028451A1 (en) * 2004-09-03 2006-03-16 3M Innovative Properties Company 1-amino 1-h-imidazoquinolines
WO2006091647A2 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
US8178677B2 (en) * 2005-02-23 2012-05-15 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
AU2006241166A1 (en) 2005-04-25 2006-11-02 3M Innovative Properties Company Immunostimulatory compositions
AU2006311871B2 (en) * 2005-11-04 2011-03-03 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
US8951528B2 (en) * 2006-02-22 2015-02-10 3M Innovative Properties Company Immune response modifier conjugates
MY150519A (en) * 2007-05-08 2014-01-30 Astrazeneca Ab Imidazoquinolines with immuno-modulating properties
CN103396415B (zh) * 2008-03-24 2016-08-10 4Sc股份有限公司 新的取代的咪唑并喹啉化合物

Also Published As

Publication number Publication date
SI2276486T1 (sl) 2014-01-31
WO2009118296A2 (en) 2009-10-01
US9073913B2 (en) 2015-07-07
CY1114648T1 (el) 2016-12-14
JP5837549B2 (ja) 2015-12-24
AU2009228769B2 (en) 2014-07-10
AU2014210573A1 (en) 2014-08-28
IL208220A0 (en) 2010-12-30
CN103396415B (zh) 2016-08-10
HK1152238A1 (en) 2012-02-24
EP2276486A2 (en) 2011-01-26
US20150335636A1 (en) 2015-11-26
JP2014043458A (ja) 2014-03-13
EA023556B1 (ru) 2016-06-30
EP2276486B1 (en) 2013-08-28
AU2009228769A1 (en) 2009-10-01
EA201001356A1 (ru) 2011-06-30
BRPI0909317B1 (pt) 2021-05-25
WO2009118296A3 (en) 2009-12-03
MX344330B (es) 2016-12-13
PT2276486E (pt) 2013-12-04
IL208220A (en) 2016-09-29
CA2719544A1 (en) 2009-10-01
JP2011515436A (ja) 2011-05-19
BRPI0909317A2 (pt) 2017-04-11
EP2386557B1 (en) 2018-01-10
SG189692A1 (en) 2013-05-31
US9446040B2 (en) 2016-09-20
ES2667054T3 (es) 2018-05-09
CN103396415A (zh) 2013-11-20
EA029926B1 (ru) 2018-05-31
AU2009228769C1 (en) 2014-11-06
EA201590628A1 (ru) 2016-03-31
CA2719544C (en) 2018-01-09
PL2276486T3 (pl) 2014-04-30
ES2436540T3 (es) 2014-01-02
NZ599446A (en) 2013-11-29
US20170029422A1 (en) 2017-02-02
AU2014210573B2 (en) 2016-05-12
KR20100134060A (ko) 2010-12-22
CN101980707B (zh) 2015-05-20
US9908880B2 (en) 2018-03-06
CN101980707A (zh) 2011-02-23
HRP20131139T1 (hr) 2014-01-03
RS53059B (en) 2014-04-30
JP2014208704A (ja) 2014-11-06
NZ588183A (en) 2012-05-25
JP5670876B2 (ja) 2015-02-18
MX2010010511A (es) 2011-04-05
US20110245289A1 (en) 2011-10-06
DK2276486T3 (da) 2013-11-25
EP2386557A1 (en) 2011-11-16
UA105764C2 (uk) 2014-06-25
ME02124B (me) 2014-04-30
KR101606219B1 (ko) 2016-03-24

Similar Documents

Publication Publication Date Title
DK2386557T3 (da) Hidtil ukendte substituerede imidazoquinoliner
EP1343784B1 (en) UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS and pharmaceutical compositions comprising the same.
US6720422B2 (en) Amide substituted imidazopyridines
AU2002345615B2 (en) Amide substituted imidazopyridines
KR100781428B1 (ko) 술폰아미드 및 술파미드 치환된 이미다조퀴놀린
JP2007262093A (ja) イミダゾナフチリジンアミン及びその製薬として許容可能の塩並びにそれらを含む医薬組成物
UA73504C2 (en) Imidazoquinolines substituted by urea